Biologics in systemic sclerosis.

Curr Pharm Biotechnol

Department of Medicinal Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University, Address: 17 Renming Street South, 3rd Section, Chengdu, Sichuan, China 610041.

Published: May 2015

Systemic sclerosis (scleroderma) is a heterogeneous autoimmune disorder characterized by collagen overproduction that leads to cutaneous and internal organs sclerosis and pulmonary arterial hypertension. SSc has high morbidity and mortality. SSc pathogenesis is uncertain. At present most therapies of SSc are symptomatic. Effective therapeutic approaches are lacking. Accompanying a growing understanding of SSc pathogenesis, various key mediators are being evaluated as the therapeutic targets. This review described the effects of these key mediators in SSc.

Download full-text PDF

Source
http://dx.doi.org/10.2174/138920101506140910150749DOI Listing

Publication Analysis

Top Keywords

systemic sclerosis
8
ssc pathogenesis
8
key mediators
8
ssc
5
biologics systemic
4
sclerosis systemic
4
sclerosis scleroderma
4
scleroderma heterogeneous
4
heterogeneous autoimmune
4
autoimmune disorder
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!